- Home
- IOTR vs NRXP Comparison
IOTR vs NRXP Comparison
Compare IOTR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOTR
- NRXP
- Stock Information
- Founded
- IOTR 2019
- NRXP 2015
- Country
- IOTR Singapore
- NRXP United States
- Employees
- IOTR N/A
- NRXP N/A
- Industry
- IOTR
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- IOTR
- NRXP Health Care
- Exchange
- IOTR NYSE
- NRXP Nasdaq
- Market Cap
- IOTR 11.5M
- NRXP 58.5M
- IPO Year
- IOTR 2025
- NRXP N/A
- Fundamental
- Price
- IOTR $0.48
- NRXP $2.88
- Analyst Decision
- IOTR
- NRXP Strong Buy
- Analyst Count
- IOTR 0
- NRXP 4
- Target Price
- IOTR N/A
- NRXP $28.50
- AVG Volume (30 Days)
- IOTR 691.1K
- NRXP 137.7K
- Earning Date
- IOTR 01-01-0001
- NRXP 08-13-2025
- Dividend Yield
- IOTR N/A
- NRXP N/A
- EPS Growth
- IOTR N/A
- NRXP N/A
- EPS
- IOTR N/A
- NRXP N/A
- Revenue
- IOTR $10,478,550.00
- NRXP N/A
- Revenue This Year
- IOTR N/A
- NRXP N/A
- Revenue Next Year
- IOTR N/A
- NRXP $230.95
- P/E Ratio
- IOTR N/A
- NRXP N/A
- Revenue Growth
- IOTR 22.27
- NRXP N/A
- 52 Week Low
- IOTR $0.31
- NRXP $1.10
- 52 Week High
- IOTR $5.98
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- IOTR N/A
- NRXP 38.54
- Support Level
- IOTR N/A
- NRXP $2.89
- Resistance Level
- IOTR N/A
- NRXP $3.15
- Average True Range (ATR)
- IOTR 0.00
- NRXP 0.14
- MACD
- IOTR 0.00
- NRXP -0.04
- Stochastic Oscillator
- IOTR 0.00
- NRXP 10.22
About IOTR IOTHREE LIMITED
iOThree Ltd is a provider of maritime digital technologies, including satellite connectivity and digitalization solutions in Singapore, focused on facilitating the maritime industry towards digital transformation. It offers shipboard infrastructure to customers by designing and installing the necessary satellite connectivity solution, IT equipment, shipboard equipment (such as equipment relating to navigation systems, automatic identification system, etc.), and JARVISS, a digitalization platform on the vessels of customers. The group's operating segments are: Satellite connectivity solution, which generates key revenue, and Digitalization and other solution. Geographically, it generates maximum revenue from Singapore, and rest from Israel, Malaysia, Vietnam, Thailand, and other regions.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.